Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

1. Quach, H.
2. Nooka, A.
3. Samoylova, O.
4. Venner, C.P.
5. Kim, K.
6. Facon, T.
7. Spencer, A.
8. Usmani, S.Z.
9. Grosicki, S.
10. Suzuki, K.
11. Delimpasi, S.
12. Weisel, K.
13. Obreja, M.
14. Zahlten-Kumeli, A.
15. Mateos, M.-V.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1111/BJH.17541 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus